Skip to main content
Erschienen in: Die Nephrologie 4/2023

20.06.2023 | IgG4-assoziierte Erkrankungen | CME

IgG4-assoziierte Nierenerkrankungen

verfasst von: Christina Thompson, Frank O. Henes, Oliver M. Steinmetz, Dr. med. Simon Melderis

Erschienen in: Die Nephrologie | Ausgabe 4/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Immunglobulin(Ig)-G4-assoziierte Erkrankung (IgG4-RD) ist eine entzündliche Systemerkrankung, die durch eine chronische Aktivierung des Immunsystems mit konsekutiver Gewebefibrose gekennzeichnet ist und eine Vielzahl verschiedener Organsysteme betreffen kann. Die häufigste Form der Nierenbeteiligung (IgG4-RKD) ist die tubulointerstitielle Nephritis (IN) mit charakteristischen Infiltraten von IgG4-positiven Plasmazellen im Interstitium und storiformer Fibrose. Seltener finden sich Formen mit glomerulärer Beteiligung sowie Harnstauungsnieren durch retroperitoneale Fibrose. Klinisch präsentiert sich die IgG4-RKD meist unspezifisch, und es findet sich lediglich eine eingeschränkte Nierenfunktion bei unauffälliger Urinanalyse. Ein erhöhtes Serum-IgG4 kann die Verdachtsdiagnose erhärten. Mittels Schnittbildgebung lassen sich zudem häufig charakteristische kortexnahe Läsionen nachweisen, welche schwer von Malignomen abzugrenzen sind. Obwohl man typischerweise ein schnelles klinisches Ansprechen der IgG4-RKD auf eine Therapie mit Glukokortikoiden findet, kommt es oft nur zu einer partiellen Verbesserung der Nierenfunktion. Rezidive sind häufig, und das optimale Management der Nachsorge und der Langzeittherapie ist unklar. Im Rahmen dieses Beitrags sollen die verschiedenen Formen der IgG4-RKD näher erläutert werden.
Literatur
1.
Zurück zum Zitat Perugino CA, Stone JH (2020) IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol 16(12):702–714PubMedCrossRef Perugino CA, Stone JH (2020) IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol 16(12):702–714PubMedCrossRef
3.
Zurück zum Zitat Saeki T et al (2010) Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int 78(10):1016–1023PubMedCrossRef Saeki T et al (2010) Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int 78(10):1016–1023PubMedCrossRef
4.
Zurück zum Zitat Kawano M, Saeki T, Nakashima H (2019) IgG4-related kidney disease and retroperitoneal fibrosis: an update. Mod Rheumatol 29(2):231–239PubMedCrossRef Kawano M, Saeki T, Nakashima H (2019) IgG4-related kidney disease and retroperitoneal fibrosis: an update. Mod Rheumatol 29(2):231–239PubMedCrossRef
5.
Zurück zum Zitat Nikiphorou E, Galloway J, Fragoulis GE (2020) Overview of IgG4-related aortitis and periaortitis. A decade since their first description. Autoimmun Rev 19(12):102694PubMedCrossRef Nikiphorou E, Galloway J, Fragoulis GE (2020) Overview of IgG4-related aortitis and periaortitis. A decade since their first description. Autoimmun Rev 19(12):102694PubMedCrossRef
6.
Zurück zum Zitat Cortazar FB, Stone JH (2015) IgG4-related disease and the kidney. Nat Rev Nephrol 11(10):599–609PubMedCrossRef Cortazar FB, Stone JH (2015) IgG4-related disease and the kidney. Nat Rev Nephrol 11(10):599–609PubMedCrossRef
7.
Zurück zum Zitat Saeki T et al (2016) Recovery of renal function after glucocorticoid therapy for IgG4-related kidney disease with renal dysfunction. Clin Exp Nephrol 20(1):87–93PubMedCrossRef Saeki T et al (2016) Recovery of renal function after glucocorticoid therapy for IgG4-related kidney disease with renal dysfunction. Clin Exp Nephrol 20(1):87–93PubMedCrossRef
8.
Zurück zum Zitat Mizushima I et al (2016) Factors related to renal cortical atrophy development after glucocorticoid therapy in IgG4-related kidney disease: a retrospective multicenter study. Arthritis Res Ther 18(1):273PubMedPubMedCentralCrossRef Mizushima I et al (2016) Factors related to renal cortical atrophy development after glucocorticoid therapy in IgG4-related kidney disease: a retrospective multicenter study. Arthritis Res Ther 18(1):273PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Hamano H et al (2001) High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344(10):732–738PubMedCrossRef Hamano H et al (2001) High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344(10):732–738PubMedCrossRef
10.
Zurück zum Zitat Kamisawa T et al (2003) A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 38(10):982–984PubMedCrossRef Kamisawa T et al (2003) A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 38(10):982–984PubMedCrossRef
11.
Zurück zum Zitat Stone JH, Zen Y, Deshpande V (2012) IgG4-related disease. N Engl J Med 366(6):539–551PubMedCrossRef Stone JH, Zen Y, Deshpande V (2012) IgG4-related disease. N Engl J Med 366(6):539–551PubMedCrossRef
12.
Zurück zum Zitat Deshpande V et al (2012) Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25(9):1181–1192PubMedCrossRef Deshpande V et al (2012) Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25(9):1181–1192PubMedCrossRef
14.
Zurück zum Zitat Thiele T, Witte T (2022) Immunoglobulin G (IgG) 4‑related diseases. Z Rheumatol 81(3):225–235PubMedCrossRef Thiele T, Witte T (2022) Immunoglobulin G (IgG) 4‑related diseases. Z Rheumatol 81(3):225–235PubMedCrossRef
15.
Zurück zum Zitat Floreani A et al (2021) IgG4-related disease: changing epidemiology and new thoughts on a multisystem disease. J Transl Autoimmun 4:100074PubMedCrossRef Floreani A et al (2021) IgG4-related disease: changing epidemiology and new thoughts on a multisystem disease. J Transl Autoimmun 4:100074PubMedCrossRef
17.
Zurück zum Zitat Zen Y et al (2009) Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol 33(12):1833–1839PubMedCrossRef Zen Y et al (2009) Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol 33(12):1833–1839PubMedCrossRef
19.
Zurück zum Zitat Umehara H et al (2021) The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 31(3):529–533PubMedCrossRef Umehara H et al (2021) The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 31(3):529–533PubMedCrossRef
20.
Zurück zum Zitat Wallace ZS et al (2015) IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol 67(9):2466–2475PubMedPubMedCentralCrossRef Wallace ZS et al (2015) IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol 67(9):2466–2475PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Ebbo M et al (2012) IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine 91(1):49–56PubMedCrossRef Ebbo M et al (2012) IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine 91(1):49–56PubMedCrossRef
22.
Zurück zum Zitat Nakashima H et al (2017) Estimation of the number of histological diagnosis for IgG4-related kidney disease referred to the data obtained from the Japan Renal Biopsy Registry (J-RBR) questionnaire and cases reported in the Japanese Society of Nephrology Meetings. Clin Exp Nephrol 21(1):97–103PubMedCrossRef Nakashima H et al (2017) Estimation of the number of histological diagnosis for IgG4-related kidney disease referred to the data obtained from the Japan Renal Biopsy Registry (J-RBR) questionnaire and cases reported in the Japanese Society of Nephrology Meetings. Clin Exp Nephrol 21(1):97–103PubMedCrossRef
23.
Zurück zum Zitat Mac K et al (2017) The incidence of IgG4-positive plasma cells staining TIN in patients with biopsy-proven tubulointerstitial nephritis. J Clin Pathol 70(6):483–487PubMedCrossRef Mac K et al (2017) The incidence of IgG4-positive plasma cells staining TIN in patients with biopsy-proven tubulointerstitial nephritis. J Clin Pathol 70(6):483–487PubMedCrossRef
24.
Zurück zum Zitat Stone JH et al (2012) Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 64(10):3061–3067PubMedPubMedCentralCrossRef Stone JH et al (2012) Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 64(10):3061–3067PubMedPubMedCentralCrossRef
25.
26.
Zurück zum Zitat Oqueka T et al (2022) Sarcoidosis as prime example of a granulomatous disease. Z Rheumatol 81(7):535–548PubMedCrossRef Oqueka T et al (2022) Sarcoidosis as prime example of a granulomatous disease. Z Rheumatol 81(7):535–548PubMedCrossRef
27.
28.
Zurück zum Zitat Takahashi N et al (2007) Renal involvement in patients with autoimmune pancreatitis: CT and MR imaging findings. Radiology 242(3):791–801PubMedCrossRef Takahashi N et al (2007) Renal involvement in patients with autoimmune pancreatitis: CT and MR imaging findings. Radiology 242(3):791–801PubMedCrossRef
29.
Zurück zum Zitat Kawano M et al (2011) Proposal for diagnostic criteria for IgG4-related kidney disease. Clin Exp Nephrol 15(5):615–626PubMedCrossRef Kawano M et al (2011) Proposal for diagnostic criteria for IgG4-related kidney disease. Clin Exp Nephrol 15(5):615–626PubMedCrossRef
30.
Zurück zum Zitat Morimoto J et al (2009) Membranoproliferative glomerulonephritis-like glomerular disease and concurrent tubulointerstitial nephritis complicating IgG4-related autoimmune pancreatitis. Intern Med 48(3):157–162PubMedCrossRef Morimoto J et al (2009) Membranoproliferative glomerulonephritis-like glomerular disease and concurrent tubulointerstitial nephritis complicating IgG4-related autoimmune pancreatitis. Intern Med 48(3):157–162PubMedCrossRef
31.
Zurück zum Zitat Shoji S, Nakano M, Usui Y (2010) IgG4-related inflammatory pseudotumor of the kidney. Int J Urol 17(4):389–390PubMedCrossRef Shoji S, Nakano M, Usui Y (2010) IgG4-related inflammatory pseudotumor of the kidney. Int J Urol 17(4):389–390PubMedCrossRef
32.
Zurück zum Zitat Sasiwimonphan K et al (2012) Renal involvement in patients with autoimmune pancreatitis: ultrasound findings. Eur J Radiol 81(5):807–810PubMedCrossRef Sasiwimonphan K et al (2012) Renal involvement in patients with autoimmune pancreatitis: ultrasound findings. Eur J Radiol 81(5):807–810PubMedCrossRef
34.
Zurück zum Zitat Jeong HJ, Shin SJ, Lim BJ (2016) Overview of IgG4-related tubulointerstitial nephritis and its mimickers. J Pathol Transl Med 50(1):26–36PubMedCrossRef Jeong HJ, Shin SJ, Lim BJ (2016) Overview of IgG4-related tubulointerstitial nephritis and its mimickers. J Pathol Transl Med 50(1):26–36PubMedCrossRef
35.
Zurück zum Zitat Saeki T et al (2021) Validation of the diagnostic criteria for IgG4-related kidney disease (IgG4-RKD) 2011, and proposal of a new 2020 version. Clin Exp Nephrol 25(2):99–109PubMedPubMedCentralCrossRef Saeki T et al (2021) Validation of the diagnostic criteria for IgG4-related kidney disease (IgG4-RKD) 2011, and proposal of a new 2020 version. Clin Exp Nephrol 25(2):99–109PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Deng C et al (2015) Histopathological diagnostic value of the IgG4+/IgG+ ratio of plasmacytic infiltration for IgG4-related diseases: a PRISMA-compliant systematic review and meta-analysis. Medicine 94(9):e579PubMedPubMedCentralCrossRef Deng C et al (2015) Histopathological diagnostic value of the IgG4+/IgG+ ratio of plasmacytic infiltration for IgG4-related diseases: a PRISMA-compliant systematic review and meta-analysis. Medicine 94(9):e579PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Yamaguchi Y et al (2012) Characteristic tubulointerstitial nephritis in IgG4-related disease. Hum Pathol 43(4):536–549PubMedCrossRef Yamaguchi Y et al (2012) Characteristic tubulointerstitial nephritis in IgG4-related disease. Hum Pathol 43(4):536–549PubMedCrossRef
38.
Zurück zum Zitat Khosroshahi A et al (2015) International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 67(7):1688–1699PubMedCrossRef Khosroshahi A et al (2015) International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 67(7):1688–1699PubMedCrossRef
39.
Zurück zum Zitat Alexander MP et al (2013) Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int 83(3):455–462PubMedCrossRef Alexander MP et al (2013) Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int 83(3):455–462PubMedCrossRef
40.
Zurück zum Zitat Kawano M et al (2023) Recent advances in IgG4-related kidney disease. Mod Rheumatol 33(2):242–251PubMedCrossRef Kawano M et al (2023) Recent advances in IgG4-related kidney disease. Mod Rheumatol 33(2):242–251PubMedCrossRef
41.
Zurück zum Zitat Wallace ZS et al (2020) The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis 79(1):77–87PubMedCrossRef Wallace ZS et al (2020) The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis 79(1):77–87PubMedCrossRef
42.
Zurück zum Zitat Miyanaga T et al (2021) Tertiary lymphoid tissue in early-stage IgG4-related tubulointerstitial nephritis incidentally detected with a tumor lesion of the ureteropelvic junction: a case report. BMC Nephrol 22(1):34PubMedPubMedCentralCrossRef Miyanaga T et al (2021) Tertiary lymphoid tissue in early-stage IgG4-related tubulointerstitial nephritis incidentally detected with a tumor lesion of the ureteropelvic junction: a case report. BMC Nephrol 22(1):34PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Inenaga J et al (2015) IgG4-related disease: a mass lesion in the Intrarenal sinus near the renal pelvis. Intern Med 54(15):1897–1900PubMedCrossRef Inenaga J et al (2015) IgG4-related disease: a mass lesion in the Intrarenal sinus near the renal pelvis. Intern Med 54(15):1897–1900PubMedCrossRef
44.
Zurück zum Zitat Kuroda N et al (2009) Chronic sclerosing pyelitis with an increased number of IgG4-positive plasma cells. Med Mol Morphol 42(4):236–238PubMedCrossRef Kuroda N et al (2009) Chronic sclerosing pyelitis with an increased number of IgG4-positive plasma cells. Med Mol Morphol 42(4):236–238PubMedCrossRef
45.
Zurück zum Zitat Lian L, Wang C, Tian JL (2016) IgG4-related retroperitoneal fibrosis: a newly characterized disease. Int J Rheum Dis 19(11):1049–1055PubMedCrossRef Lian L, Wang C, Tian JL (2016) IgG4-related retroperitoneal fibrosis: a newly characterized disease. Int J Rheum Dis 19(11):1049–1055PubMedCrossRef
47.
Zurück zum Zitat Stone JH et al (2015) Diagnostic approach to the complexity of IgG4-related disease. Mayo Clin Proc 90(7):927–939PubMedCrossRef Stone JH et al (2015) Diagnostic approach to the complexity of IgG4-related disease. Mayo Clin Proc 90(7):927–939PubMedCrossRef
48.
Zurück zum Zitat Carruthers MN et al (2015) The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 74(1):14–18PubMedCrossRef Carruthers MN et al (2015) The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 74(1):14–18PubMedCrossRef
49.
Zurück zum Zitat Cheuk W, Chan JK (2010) IgG4-related sclerosing disease: a critical appraisal of an evolving clinicopathologic entity. Adv Anat Pathol 17(5):303–332PubMedCrossRef Cheuk W, Chan JK (2010) IgG4-related sclerosing disease: a critical appraisal of an evolving clinicopathologic entity. Adv Anat Pathol 17(5):303–332PubMedCrossRef
50.
Zurück zum Zitat Khosroshahi A et al (2014) Brief Report: spuriously low serum IgG4 concentrations caused by the prozone phenomenon in patients with IgG4-related disease. Arthritis Rheumatol 66(1):213–217PubMedCrossRef Khosroshahi A et al (2014) Brief Report: spuriously low serum IgG4 concentrations caused by the prozone phenomenon in patients with IgG4-related disease. Arthritis Rheumatol 66(1):213–217PubMedCrossRef
51.
Zurück zum Zitat Brito-Zerón P et al (2016) IgG4-related disease: advances in the diagnosis and treatment. Best Pract Res Clin Rheumatol 30(2):261–278PubMedCrossRef Brito-Zerón P et al (2016) IgG4-related disease: advances in the diagnosis and treatment. Best Pract Res Clin Rheumatol 30(2):261–278PubMedCrossRef
53.
Zurück zum Zitat Sasaki T et al (2018) Risk factors of relapse following glucocorticoid tapering in IgG4-related disease. Clin Exp Rheumatol 36(Suppl 112(3)):186–189PubMed Sasaki T et al (2018) Risk factors of relapse following glucocorticoid tapering in IgG4-related disease. Clin Exp Rheumatol 36(Suppl 112(3)):186–189PubMed
54.
Zurück zum Zitat Saeki T et al (2013) The clinical course of patients with IgG4-related kidney disease. Kidney Int 84(4):826–833PubMedCrossRef Saeki T et al (2013) The clinical course of patients with IgG4-related kidney disease. Kidney Int 84(4):826–833PubMedCrossRef
55.
Zurück zum Zitat Yamada K et al (2017) New clues to the nature of immunoglobulin G4-related disease: a retrospective Japanese multicenter study of baseline clinical features of 334 cases. Arthritis Res Ther 19(1):262PubMedPubMedCentralCrossRef Yamada K et al (2017) New clues to the nature of immunoglobulin G4-related disease: a retrospective Japanese multicenter study of baseline clinical features of 334 cases. Arthritis Res Ther 19(1):262PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Wallace ZS et al (2015) Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis 74(1):190–195PubMedCrossRef Wallace ZS et al (2015) Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis 74(1):190–195PubMedCrossRef
58.
Zurück zum Zitat Masaki Y et al (2017) A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease. Mod Rheumatol 27(5):849–854PubMedCrossRef Masaki Y et al (2017) A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease. Mod Rheumatol 27(5):849–854PubMedCrossRef
59.
Zurück zum Zitat Wu Q et al (2017) Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: a preliminary randomized controlled trial. Int J Rheum Dis 20(5):639–646PubMedCrossRef Wu Q et al (2017) Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: a preliminary randomized controlled trial. Int J Rheum Dis 20(5):639–646PubMedCrossRef
60.
Zurück zum Zitat Yunyun F et al (2017) Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids. Sci Rep 7(1):6195PubMedPubMedCentralCrossRef Yunyun F et al (2017) Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids. Sci Rep 7(1):6195PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Khosroshahi A et al (2010) Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 62(6):1755–1762PubMedCrossRef Khosroshahi A et al (2010) Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 62(6):1755–1762PubMedCrossRef
62.
Zurück zum Zitat Khosroshahi A, Stone JH (2011) Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol 23(1):67–71PubMedCrossRef Khosroshahi A, Stone JH (2011) Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol 23(1):67–71PubMedCrossRef
63.
Zurück zum Zitat Wang L et al (2018) Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. Arthritis Res Ther 20(1):65PubMedPubMedCentralCrossRef Wang L et al (2018) Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. Arthritis Res Ther 20(1):65PubMedPubMedCentralCrossRef
64.
Zurück zum Zitat Yunyun F et al (2019) Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology 58(1):52–60PubMedCrossRef Yunyun F et al (2019) Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology 58(1):52–60PubMedCrossRef
65.
Zurück zum Zitat Takanashi S, Kaneko Y, Takeuchi T (2019) Effectiveness of tacrolimus on IgG4-related disease. Mod Rheumatol 29(5):892–894PubMedCrossRef Takanashi S, Kaneko Y, Takeuchi T (2019) Effectiveness of tacrolimus on IgG4-related disease. Mod Rheumatol 29(5):892–894PubMedCrossRef
66.
Zurück zum Zitat de Pretis N et al (2017) Azathioprine maintenance therapy to prevent relapses in autoimmune pancreatitis. Clin Transl Gastroenterol 8(4):e90PubMedPubMedCentralCrossRef de Pretis N et al (2017) Azathioprine maintenance therapy to prevent relapses in autoimmune pancreatitis. Clin Transl Gastroenterol 8(4):e90PubMedPubMedCentralCrossRef
67.
Zurück zum Zitat Pozdzik AA et al (2012) Azathioprine as successful maintenance therapy in IgG4-related tubulointerstitial nephritis. Clin Kidney J 5(3):225–228PubMedPubMedCentralCrossRef Pozdzik AA et al (2012) Azathioprine as successful maintenance therapy in IgG4-related tubulointerstitial nephritis. Clin Kidney J 5(3):225–228PubMedPubMedCentralCrossRef
68.
Zurück zum Zitat Khosroshahi A et al (2012) Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine 91(1):57–66PubMedCrossRef Khosroshahi A et al (2012) Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine 91(1):57–66PubMedCrossRef
69.
Zurück zum Zitat Hart PA et al (2013) Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 62(11):1607–1615PubMedCrossRef Hart PA et al (2013) Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 62(11):1607–1615PubMedCrossRef
70.
Zurück zum Zitat Carruthers MN et al (2015) Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 74(6):1171–1177PubMedCrossRef Carruthers MN et al (2015) Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 74(6):1171–1177PubMedCrossRef
71.
Zurück zum Zitat Ebbo M et al (2017) Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. PLoS ONE 12(9):e183844PubMedPubMedCentralCrossRef Ebbo M et al (2017) Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. PLoS ONE 12(9):e183844PubMedPubMedCentralCrossRef
72.
Zurück zum Zitat Mattoo H et al (2016) Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol 138(3):825–838PubMedPubMedCentralCrossRef Mattoo H et al (2016) Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol 138(3):825–838PubMedPubMedCentralCrossRef
73.
Zurück zum Zitat Masamune A et al (2017) Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut 66(3):487–494PubMedCrossRef Masamune A et al (2017) Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut 66(3):487–494PubMedCrossRef
74.
Zurück zum Zitat Arai H et al (2020) Long-term changes in renal function after treatment initiation and the importance of early diagnosis in maintaining renal function among IgG4-related tubulointerstitial nephritis patients in Japan. Arthritis Res Ther 22(1):261PubMedPubMedCentralCrossRef Arai H et al (2020) Long-term changes in renal function after treatment initiation and the importance of early diagnosis in maintaining renal function among IgG4-related tubulointerstitial nephritis patients in Japan. Arthritis Res Ther 22(1):261PubMedPubMedCentralCrossRef
75.
Zurück zum Zitat Evans RDR et al (2019) Clinical manifestations and long-term outcomes of IgG4-related kidney and retroperitoneal involvement in a United Kingdom IgG4-related disease cohort. Kidney Int 4(1):48–58 Evans RDR et al (2019) Clinical manifestations and long-term outcomes of IgG4-related kidney and retroperitoneal involvement in a United Kingdom IgG4-related disease cohort. Kidney Int 4(1):48–58
76.
Zurück zum Zitat Boffa JJ, Esteve E, Buob D (2020) Renal involvement in IgG4-related disease. Presse Med 49(1):104017PubMedCrossRef Boffa JJ, Esteve E, Buob D (2020) Renal involvement in IgG4-related disease. Presse Med 49(1):104017PubMedCrossRef
77.
Zurück zum Zitat Lanzillotta M, Mancuso G, Della-Torre E (2020) Advances in the diagnosis and management of IgG4 related disease. BMJ 369:m1067PubMedCrossRef Lanzillotta M, Mancuso G, Della-Torre E (2020) Advances in the diagnosis and management of IgG4 related disease. BMJ 369:m1067PubMedCrossRef
78.
Zurück zum Zitat Perugino CA et al (2017) Emerging treatment models in rheumatology: IgG4-related disease: insights into human immunology and targeted therapies. Arthritis Rheumatol 69(9):1722–1732PubMedPubMedCentralCrossRef Perugino CA et al (2017) Emerging treatment models in rheumatology: IgG4-related disease: insights into human immunology and targeted therapies. Arthritis Rheumatol 69(9):1722–1732PubMedPubMedCentralCrossRef
80.
Zurück zum Zitat Yamamoto M et al (2016) Efficacy of abatacept for IgG4-related disease over 8 months. Ann Rheum Dis 75(8):1576–1578PubMedCrossRef Yamamoto M et al (2016) Efficacy of abatacept for IgG4-related disease over 8 months. Ann Rheum Dis 75(8):1576–1578PubMedCrossRef
81.
Zurück zum Zitat Matza MA et al (2022) Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study. Lancet Rheumatol 4(2):e105–e112PubMedCrossRef Matza MA et al (2022) Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study. Lancet Rheumatol 4(2):e105–e112PubMedCrossRef
82.
Zurück zum Zitat Akiyama M, Takeuchi T (2018) IgG4-related disease: beyond glucocorticoids. Drugs Aging 35(4):275–287PubMedCrossRef Akiyama M, Takeuchi T (2018) IgG4-related disease: beyond glucocorticoids. Drugs Aging 35(4):275–287PubMedCrossRef
85.
Zurück zum Zitat Yamamoto M et al (2019) A case with good response to belimumab for lupus nephritis complicated by IgG4-related disease. Lupus 28(6):786–789PubMedCrossRef Yamamoto M et al (2019) A case with good response to belimumab for lupus nephritis complicated by IgG4-related disease. Lupus 28(6):786–789PubMedCrossRef
87.
Zurück zum Zitat Kaneko N et al (2022) Orchestration of Immune Cells Contributes to Fibrosis in IgG4-Related Disease. Immuno 2(1):170–184CrossRef Kaneko N et al (2022) Orchestration of Immune Cells Contributes to Fibrosis in IgG4-Related Disease. Immuno 2(1):170–184CrossRef
90.
Zurück zum Zitat Simpson RS, Lau SKC, Lee JK (2020) Dupilumab as a novel steroid-sparing treatment for IgG4-related disease. Ann Rheum Dis 79(4):549–550PubMedCrossRef Simpson RS, Lau SKC, Lee JK (2020) Dupilumab as a novel steroid-sparing treatment for IgG4-related disease. Ann Rheum Dis 79(4):549–550PubMedCrossRef
91.
Zurück zum Zitat Yamamoto M, Yoshikawa N, Tanaka H (2022) Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis. Ann Rheum Dis 81(3):e50PubMedCrossRef Yamamoto M, Yoshikawa N, Tanaka H (2022) Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis. Ann Rheum Dis 81(3):e50PubMedCrossRef
Metadaten
Titel
IgG4-assoziierte Nierenerkrankungen
verfasst von
Christina Thompson
Frank O. Henes
Oliver M. Steinmetz
Dr. med. Simon Melderis
Publikationsdatum
20.06.2023

Weitere Artikel der Ausgabe 4/2023

Die Nephrologie 4/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.